CLEAN : World conference meets on silent epidemic hepatitis

The video discusses hepatitis as a silent epidemic, highlighting the lack of symptoms and the long time it takes for them to appear. It addresses the challenges in diagnosing the disease, with a large number of people remaining undiagnosed. The video also explores the role of pharmaceutical companies in controlling drug patents, which limits access to affordable generics. Finally, it touches on the financial barriers that prevent many from accessing necessary treatments.

What is one reason hepatitis is considered a silent epidemic?

• It is a well-known disease.

• It often goes undiagnosed for many years.

• It is easily diagnosed.

• It has very loud symptoms.

How many people are estimated to be undiagnosed with hepatitis globally?

• About 50 million

• About 500 million

• About 10 million

• About 300 million

What is a major barrier to accessing hepatitis treatment in many countries?

• Lack of hospitals

• Lack of awareness

• Pharmaceutical patents

• Shortage of doctors

Why might generic drugs not be available in some countries?

• There is no demand for them.

• Pharmaceutical companies do not allow it.

• They are not effective.

• They are too expensive to produce.

What financial challenge do patients face in accessing hepatitis treatment?

• High cost of doctor consultations

• Lack of insurance coverage

• Need to import drugs from other countries

• High cost of local production